Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H10O4 |
| Molecular Weight | 146.1412 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12OC[C@@H](O)[C@@]1([H])OC[C@@H]2O
InChI
InChIKey=KLDXJTOLSGUMSJ-JGWLITMVSA-N
InChI=1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/s1
Isosorbide is an effective hyperosmotic agent which can be administered orally without gastrointestinal irritation. It is absorbed quantitatively and more than 95% of the administered dose is excreted unchanged in the urine. Oral administration of a 50% solution to rabbits or man results in prompt increases in osmolarity of the serum and profound decreases in intraocular pressure. The drug proves useful in acute primary and secondary glaucomas, and as preoperative medication for various surgical procedures including cataract extraction, retinal detachment, corneal transplant, and glaucoma operations.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | ISMOTIC Approved UseIsosorbide Mononitrate Extended-Release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1.28736002E11 |
|||
| Palliative | ISMOTIC Approved UseIsosorbide Mononitrate Extended-Release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1.28736002E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.16 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4695381/ |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4695381/ |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Isosorbide delays gentamicin-induced vestibular sensory cell death. | 2005 |
|
| Manganese superoxide dismutase overexpression changes plating efficiency bidirectionally according to change in redox for SaOS2 human osteosarcoma cell line. | 2005 Apr |
|
| BiDil raises questions about race as a marker. | 2005 Aug |
|
| Short-term medical management of hydrocephalus. | 2005 Aug |
|
| The impact of race on response to RAAS inhibition. | 2005 Aug |
|
| Synthesis and structure activity relationships (SAR) of a new class of potent and selective butyrylcholinesterase inhibitors. | 2005 Dec 15 |
|
| Novel isosorbide-based substrates for human butyrylcholinesterase. | 2005 Dec 15 |
|
| Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo. | 2005 Jul |
|
| [Comparative study of propranolol versus propranolol plus isosorbide 5-mononitrate in portal hypertension in cirrhotics. Evaluating splanchnic hemodynamics with color Doppler ultrasound]. | 2005 Jul-Sep |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
| The coming of age of multicultural medicine. | 2005 Mar |
|
| [Nitric oxide and cardiologic drugs]. | 2005 May |
|
| Hydrogen peroxide overload increases adriamycin-induced apoptosis of SaOS(2)FM, a manganese superoxide dismutase-overexpressing human osteosarcoma cell line. | 2005 May |
|
| Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. | 2005 Nov |
|
| BiDil: false promises: faulty statistics and reasoning have lead to the first "racial medicine". | 2005 Nov-Dec |
|
| Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. | 2005 Oct |
|
| Cooperative type of platelet hypersensitivity to ADP. | 2005 Sep |
|
| Cerebral blood flow during supine rest and the first minute of head-up tilt in patients with orthostatic intolerance. | 2005 Sep |
|
| Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. | 2005 Sep 30 |
|
| Antidiuretic hormone and osmolality in isosorbide therapy and glycerol test. | 2006 |
|
| Coronary artery spasm and the polymorphisms of the endothelial nitric oxide synthase gene. | 2006 Apr |
|
| Effectiveness of oral route isosorbide 5-mononitrate on peritoneal solute and fluid transports in CAPD patients. | 2006 Aug |
|
| Co- and terpolyesters based on isosorbide and succinic acid for coating applications: synthesis and characterization. | 2006 Dec |
|
| [Usefulness of sublingual isosorbide to assess the reversibility of pulmonary hypertension in cardiac transplant candidates]. | 2006 Feb |
|
| Use of simultaneous pressure and velocity measurements to estimate arterial wave speed at a single site in humans. | 2006 Feb |
|
| Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. | 2006 Feb |
|
| Cholesteric polymer guest-host mixture with circularly polarized fluorescence: two ways for phototuning of polarization and its intensity. | 2006 Feb 23 |
|
| IMOP: randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour - clinical trial with analyses of efficacy, cost effectiveness and acceptability. | 2006 Jul 25 |
|
| Cerebrovascular blood flow during the near syncopal phase of head-up tilt test: a comparative study in different types of neurally mediated syncope. | 2006 Mar |
|
| Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. | 2006 Mar |
|
| Endothelial dysfunction in patients with ulcerative colitis. | 2006 Mar |
|
| Should drug therapy be personalized based on race? | 2006 Mar |
|
| Composition analysis of two batches of polysorbate 60 using MS and NMR techniques. | 2006 Mar 18 |
|
| Quantification of isosorbide 5-mononitrate in human plasma by liquid chromatography-tandem mass spectrometry using atmospheric pressure photoionization. | 2006 Mar 7 |
|
| Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. | 2006 May |
|
| Aortic responsiveness to nitric oxide is affected by seasonal variation. | 2006 May |
|
| Allergic and nonallergic reactions to nitroglycerin. | 2006 May-Jun |
|
| Effects of simple and complex motion patterns on gene expression of chondrocytes seeded in 3D scaffolds. | 2006 Nov |
|
| Organic solvents as vehicles for precipitating liquid embolics: a comparative angiotoxicity study with superselective injections of swine rete mirabile. | 2006 Oct |
|
| Vestibular evoked myogenic potentials in acute acoustic trauma. | 2006 Oct |
|
| [Prevention of variceal bleeding and measurement of hepatic vein pressure gradient]. | 2006 Sep |
|
| [Milestones of cardiovascular therapy. III. Nitroglycerin]. | 2007 |
|
| Neuropsychiatric consequences of cardiovascular medications. | 2007 |
|
| High performance liquid chromatography-electrospray ionization mass spectrometric determination of isosorbide 5-mononitrate in human plasma. | 2007 Feb 1 |
|
| Value of symptoms to predict tilt testing outcome in patients with clinical suspicion of vasovagal syncope. | 2007 Jul |
|
| Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. | 2007 Jun 12 |
|
| Potential and utilization of thermophiles and thermostable enzymes in biorefining. | 2007 Mar 15 |
|
| Prevention of recurrent esophageal variceal hemorrhage: review and current recommendations. | 2007 Nov-Dec |
|
| Occlusal management for a patient with aural symptoms of unknown etiology: a case report. | 2007 Sep 12 |
|
| Physicochemical characterisation of a novel thermogelling formulation for percutaneous penetration of 5-aminolevulinic acid. | 2008 Jun |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
211-492-3
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
6057
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | RxNorm | ||
|
1352008
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200660
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
m6540
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | Merck Index | ||
|
ISOSORBIDE
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
DTXSID5046196
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
40725
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
652-67-5
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
3105
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
D007547
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
WXR179L51S
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
100000082855
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
12597
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
1501
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
SUB08334MIG
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
6433
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
C60773
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
DB09401
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY | |||
|
WXR179L51S
Created by
admin on Fri Dec 15 15:16:19 UTC 2023 , Edited by admin on Fri Dec 15 15:16:19 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
